Patient-specific Fluorescence Aberration Profiles during Longitudinal Clinical Trials

Home > Science Hub > Patient-specific Fluorescence Aberration Profiles during Longitudinal Clinical Trials
Back to the list

June 8, 2018

Dominic Gagnon, Damien Montamat-Sicotte, Josianne Chagnon-Choquet, Vicky Sgouroudis, Philippe Pouliot & Virginia Litwin

Patient-specific Fluorescence Aberration Profiles during Longitudinal Clinical Trials, AAPS 2018

Patient-specific Fluorescence Aberration Profiles during Longitudinal Clinical Trials

Download poster

You might also be interested by

CellTalk Blog

How to Select the Optimal TBNK Panel: Matching Immune Monitoring to Clinical Context

November 25, 2025

Immune Monitoring

More info

CellTalk Blog

ELISpot vs. ICS: Optimizing Immune Monitoring in Clinical Trials with the Right Functional Assay

November 19, 2024

Immune Monitoring

More info

CellTalk Blog

Measure Target Engagement With Receptor Occupancy Assays by Flow Cytometry

September 17, 2024

Immune Monitoring

More info

Brochures & Infographics

High Performance Technologies for Cytokine Measurement

July 29, 2024

Immune Monitoring

More info